Atherosclerosis
Volume 143, Issue 2 , Pages 315-326 , April 1999

Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits

Received 18 March 1998 ,Revised 9 September 1998 ,Accepted 26 November 1998.

References 

  1. Levy BI, Safar ME. Remodeling of the vascular system in response to hypertension and drug therapy, Clin Exp Pharm Physiol 1992;19 Suppl:33.
  2. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe Heritable Hyperlipidemic rabbit. Hypertension. 1990;15:327–331
  3. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe Heritable Hyperlipidemic rabbit. Hypertension. 1992;20:473–477
  4. Chobanian AV, Hope S, Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe Heritable Hyperlipidemic rabbit. Hypertension. 1995;25:1306–1310
  5. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15 Suppl. 5:S65–72.
  6. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis. 1994;108:61–72
  7. Kowala MC, Recce R, Beyer S, Aberg G. Regression of early atherosclerosis in hyperlipidemic hamsters induced by Fosinopril and captopril. J. Cardiovasc. Pharmacol. 1995;25:179–186
  8. Schuh TR, Blehmn DJ, Friedrich GE, Mcmahon EG, Blaine EH. Differential effects of renin-angiotensin blockade on atherogenesis in cholesterol-fed rabbits. J. Clin. Invest. 1993;91:1453–1458
  9. Charpiot P, Rolland PH, Friggi A. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler. Thromb. 1993;13:1125–1138
  10. Kowala MC. Captopril decreases accelerated atherosclerosis in hypertensive one clip rats fed cholesterol. Drug. Dev. Res. 1993;29:100–107
  11. Becker RHA, Wiemer G, Line W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18 Suppl 2:S110–15.
  12. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132–141
  13. Olbinskaya LI, Golubev SA, Bolshakova TD. Influence of benazepril and captopril on blood pressure; glucocorticoids and progesterone in essential hypertensives. J. Hum. Hypertens. 1993;7:603–606
  14. Zimmerman MB, Barclay BW, Lehmann M, Norman JA. Effects of chronic administration of angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin. Exp. Hypertens. A. 1987;9:473–476
  15. Criscione L, Bradley W, Bühlmayer P, et al.  Valsartan: preclinical and clinical profile of an antihypertensive, angiotensin II-antagonist. Cardiovasc. Drug. Rev. 1995;13:230–250
  16. Bukenburg B, Schnell C, Baum HP, Cumin F, Wood J. Prolonged angiotensin II antagonism in spontaneously hypertensive rats: hemodynamic and biochemical consequences. Hypertension. 1991;18:278–288
  17. Wood JM, Schnell CR, Levens NR. Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats. Hypertension. 1993;21:1056–1061
  18. Miura T, Komori M, Takahashi T, Shiota K. Computerized three-dimensional reconstruction of human embryos and their organs using the “NIH image” software. Kaibogaku. Zasshi. 1995;70:353–361
  19. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K. Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis. 1993;99:79–86
  20. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissue. Am. J. Pathol. 1989;134:733–739
  21. Tsukada T, Rosenfeld M, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesion: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis. 1986;6:601–613
  22. Tsukada T, Tippens D, Mar H, Gordon D, Ross R, Gown AM. HHF35: a muscle-actin-specific monoclonal antibody I: immunocytochemical and biochemical characterization. Am. J. Pathol. 1987;126:51–60
  23. Rekhter M, Nicholls S, Ferguson M, Gordon D. Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler. Thromb. 1993;13:609–617
  24. Rekhter MD, Gordon D. Does platelet-derived growth factor-A chain stimulate proliferation of arterial mesenchymal cells in human atherosclerotic plaques?. Circ. Res. 1994;75:410–417
  25. Rekhter MD, Gordon D. Active proliferation of different cell types; including lymphocytes; in human atherosclerotic plaques. Am. J. Pathol. 1995;147:668–677
  26. Rosenfeld ME, Palinski W, Yla-herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid–protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336–349
  27. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186–188
  28. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II; AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am. J. Pathol. 1991;139:1291–1296
  29. Gianco SH, Brown SA, Via DP, Bradley WA. The β-VLDL receptor pathway of mourn p388D macrophages. J. Lipid. Res. 1986;27:412–420
  30. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins; comparison of very low density lipoprotein from subjects with type III, IV and V hyperlipoproteiniemia. Arterioscler. Thromb. 1991;11:221–233
  31. Yui S, Sasaki T, Miyazaki A, Horiuchi S, Yamazaki M, Induction of murine macrophage growth by modified LDLs, Arterioscler Thromb 1993;13:331–37.
  32. Parthasarathy S, Quinn MT, Schwenke DC, Carew TE, Steinberg D. Oxidative modification of beta-very low density lipoprotein; potential role in monocyte recruitment and foam cell formation. Arteriosclerosis. 1989;9:398–404
  33. Gianturco SH, Lin AHY, Hwang SLC, Young Y, Brown SA, Via DP, et al. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoprotein. J. Clin. Invest. 1989;82:1633–1643
  34. Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU. The preferential human mononuclear leukocyte chemotactic activity of the substituent peptides of angiotensin II. Biochem. Biophys. Res. Commun. 1980;97:1097–1102
  35. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to aortic endothelial cells. Clin. Res. 1994;42:15A
  36. Weinstock JV, Blum AM. Isolated liver granulomas of murine schistosoma mansoni contain components of the angiotensin system. J. Immunol. 1983;131:2529–2532
  37. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, et al. Macrophage and myofibroblast proliferation in remant kidney: role of angiotensin II. Kidney. Intern. Suppl. 1997;52:221–225
  38. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558–563
  39. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res. 1993;72:1202–1210
  40. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 1987;92:181–187
  41. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 1987;148:1482–1489
  42. Bath PMW, Hassall DG, Gladwin AM, Palmer PMJ, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler. Thromb. 1991;11:254–260
  43. Gerrity RG. The role of the monocyte in atherogenesis I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am. J. Pathol. 1981;103:181–190
  44. Kowala MC, Mazzucco CE, Hartl KS. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters; octimibate and BMY 42393 suppress monocyte chemotaxis; macrophage cholesterol ester accumulation; scavenger receptor activity and tumor necrosis factor production. Arterioscler. Thromb. 1993;13:435–444
  45. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Human. pathology. 1993;24:534–539

PII: S0021-9150(98)00309-8

Atherosclerosis
Volume 143, Issue 2 , Pages 315-326 , April 1999

Article Tools

* Image Usage & Resolution